PAP 2023: Diana Villanova Discusses Best Practices and Industry Standards at Access PAP 2023

A survey study takes a closer look into which medications patients would like to have deprescribed, along with the reasons and factors influencing that decision.

Renier Brentjens, MD, PhD outlines the evolution of the space, while offering ways to boost patient access to these treatments.

Access USA converges in Philadelphia to explore new—and needed—solutions to boost patient outcomes.

Brandon Newman joins The Pharmaceutical Commerce Podcast to discuss the evolving role of PBMs, including the importance of drug price transparency.

The key strategies for reducing or eliminating post-prescription abandonment.

A look at the prevailing factors impacting treatment access in 2025.